FDA approval and launch
BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, has announced the US Food and Drug Administration clearance and launch of the BD ProbeTec™ Trichomonas vaginalis Qx Amplified DNA Assay for the direct qualitative detection of T. vaginalis DNA in endocervical and vaginal samples as well as neat urine specimens to aid in the diagnosis of trichomoniasis on the BD Viper™ System with XTR™ Technology.
You must sign in to continue reading this article
Hide related content:
Show related content
read more
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: ebercott Tags: *** Editor's Pick Latest News Source Type: news